Phosphotope
(ICP-322)Phase 2Small molecule
Phosphotope is one of 25 small molecule programs targeting Prurigo Nodularis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
25 competitors in Prurigo Nodularis
#DrugCompanyPhaseTrials
1Rinvoq
AbbVieApproved
Nubain
AAultman Health Foundation
Approved
Jakafi
IncytePhase 3
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Calcineurin Inhibitors
SanofiPhase 3
Povorcitinib
IncytePhase 3
Cibinqo
PfizerPhase 2
Serlopitant
VVyne Therapeutics Inc.
Phase 3
Stapokibart
CChengdu Kangnuoxing Biopharma,Inc.
Phase 3
Rocatinlimab
AmgenPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
PHOSPHOTOPE
NDA NDA010927
Jan 1, 1982
SODIUM PHOSPHATE P 32
NDA NDA011777
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ICP-322. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMallinckrodt